<DOC>
	<DOCNO>NCT00264290</DOCNO>
	<brief_summary>The purpose study determine whether treatment valganciclovir decrease T cell activation level among HIV-infected patient asymptomatic cytomegalovirus ( CMV ) co-infection , potentially improve immune response antiretroviral therapy .</brief_summary>
	<brief_title>Valganciclovir Reduce T Cell Activation HIV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>Infection HIV &gt; 1 year duration . Age &gt; 18 Cytomegalovirus ( CMV ) antibody positive . All Cluster Differentiation 4 ( CD4 ) + T cell count last year screen &lt; 350 cells/mm3 On stable highly addictive antiretroviral therapy ( HAART ) regimen ( DHHS definition ) precede 6 month . 90 % adherence antiretroviral therapy within precede 30 day . Females childbearing potential must negative serum pregnancy test screen subject must agree use doublebarrier method contraception throughout study period . Screening % Cluster differentiation 38 ( CD38 ) + Human leukocyte antigenDrelated ( HLADR ) + Cluster differentiation 8 ( CD8 ) + T cell &gt; 10 % Patients intend modify antiretroviral therapy next 16 week . Serious illness require hospitalization parental antibiotic within precede 3 month . Evidence active symptomatic CMV endorgan disease . Treatment valganciclovir ganciclovir past 30 day . Concurrent treatment immunomodulatory drug . Concurrent treatment nephrotoxic drug Screening absolute neutrophil count &lt; 1,000 cells/mm3 , platelet count &lt; 100,000 cells/mm3 , hemoglobin &lt; 8mg/dL , estimate creatinine clearance &lt; 50 mL/minute . Men consider child also exclude give potential effect valganciclovir spermatogenesis . Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>CMV</keyword>
	<keyword>T Cell activation</keyword>
	<keyword>Valganciclovir</keyword>
</DOC>